Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, outlines a study evaluating a 2+1 T-cell bispecific (TCB) antibody immunotherapy for acute myeloid leukemia (AML). The T-cell receptor (TCR)-like TCB targets the intracellular tumor antigen Wilms tumor 1 (WT1) in the context of human leukocyte antigen allele A*02 (HLA-A2). Preclinical data indicates TCR-like TCBs targeting intracellular tumor antigens are a promising tool for cancer immunotherapy. Interestingly, combination of WT1-TCB with lenalidomide further enhanced antibody-mediated T-cell cytotoxicity against primary AML cells. Prof. Subklewe suggests that in a future clinical trial WT1-TCB efficacy can be increased with the addition of lenalidomide. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.